ACT’s Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine
October 21 2013 - 8:30AM
Business Wire
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in
the field of regenerative medicine, announced today that its chief
scientific officer, Robert Lanza, M.D., will be delivering a
Keynote lecture at the “World Conference on Regenerative Medicine”
being held in Leipzig, Germany October 23-25th. The Conference is
considered one of the world's largest and most influential events
in stem cells and regenerative medicine, and provides a platform
that brings scientists with an academic, clinical and industrial
background together. Dr. Lanza’s Lecture, entitled “ES and iPS
Cells – Moving into the Clinic,” will take place at 9:00 a.m. at
the Congress Center Leipzig.
The World Conference will, as in past years, encompass a broad
range of topics in regenerative medicine from biomaterials to
biomarkers as well as regulation and stem cell technologies. The
organizers expect more than 1,000 attendees and hundreds of papers
with ground-breaking scientific insights and new results.
Furthermore, the conference will host a large exhibition where
international researchers and biotechnology companies can
demonstrate the reach of current technology’s translation and the
implementation of research in products. In addition to Dr. Lanza’s
Keynote Lecture, the Conference will include presentations on cell
and immunotherapy, stem cells, cell and tissue engineering,
biomaterials and tissue interaction, models of regeneration,
molecular mechanisms of regeneration, diagnostic and imaging of
regeneration, and regulatory affairs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company
applying cellular technology in the field of regenerative medicine.
For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, the relevance and applicability of clinical
trials in animals to studying the effect of products in humans,
future growth in animal and human research and development
programs, potential new applications of and expanded indications
covering our technology, the effects of donorless sources of stem
cells on potency and the risk of communicable diseases in the
manufacturing context, the existence and size of potential or
existing market opportunities for the company, the effect of the
company’s products on the medical needs and quality of life of
pets, and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements
that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates,” and similar expressions) should also be
considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for and
limited sources of future capital, failures or delays in obtaining
regulatory approval of products, risks inherent in the development
and commercialization of potential products, reliance on new and
unproven technology in the development of products, protection of
our intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the Quarterly
Report on Form 10-Q for the three months ended June 30, 2013.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the company’s management at the time they are made,
and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the company’s management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the
Company’s clinical trials will be successful.
Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo
PartnersDavid Schull, 212-845-4271